Psoriasis breakthrough: lower drug doses may work just as well

NCT ID NCT04340076

Completed Disease control Sponsor: Radboud University Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether psoriasis patients who are stable on biologic drugs (IL17 or IL23 inhibitors) can safely reduce their dose without their skin condition getting worse. Researchers enrolled 244 adults with plaque psoriasis who had been on a normal dose for at least 6 months. Participants were randomly assigned to either continue their usual dose or gradually lower it. The goal was to see if dose reduction is as effective as standard care in preventing persistent flares.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IL17 and IL23 inhibitors (Secukinumab, Ixekizumab, Brodalumab, Guselkumab)
What this could lead to: If successful, this could show that many psoriasis patients can safely lower their biologic dose without flare-ups, reducing side effects and costs.
What could go wrong: This is a completed Phase 4 study with 244 participants, so results are available but may not apply to all patients. Dose reduction might not work for everyone and could lead to disease flares.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PSORIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriasis Skin Diseases, Papulosquamous skin disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PSORIASIS PSORIASIS VULGARIS

Contacts and locations

Locations

AZ Maria Middelares

Ghent, Belgium
AZ St Lucas

Ghent, Belgium
Amphia Hospital

Breda, Netherlands
Bravis hospital

Bergen op Zoom, Netherlands
CHU Liege

Liège, Belgium
Catharina hospital

Eindhoven, Netherlands
Dermatologie Maldegem

Maldegem, Belgium
Erasmus MC

Rotterdam, Netherlands
Ghent University Hospital

Ghent, 9000, Belgium
Maastricht UMC

Maastricht, Netherlands
Máxima Medisch Centrum

Veldhoven, Netherlands
Radboudumc

Nijmegen, 6500HB, Netherlands
Slingeland hospital

Doetinchem, Netherlands
UCL Saint Luc

Leuven, Belgium
ULB Erasme

Brussels, Belgium
UMC Groningen

Groningen, Netherlands
UMC Utrecht

Utrecht, Netherlands
UZ Leuven

Leuven, Belgium
Ziekenhuisgroep Twente

Almelo, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.